Display Settings:

Format

Send to:

Choose Destination
    Best Pract Res Clin Rheumatol. 2005 Feb;19(1):179-89.

    The role of biologicals in early rheumatoid arthritis.

    Source

    Division of Rheumatology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.

    Abstract

    Recent emphasis on early diagnosis and treatment of rheumatoid arthritis (RA) to improve long-term disease outcome has raised important questions about optimal therapy for early RA. With an expanding armamentarium of disease-modifying antirheumatic drugs including biological agents, there are now several therapeutic choices available to clinicians. However, at early stages of arthritis, difficulty in accurately predicting individual prognosis and response to therapy continues to pose a significant challenge. Future research in biomarkers of progressive, erosive disease and controlled trials to establish the most effective therapies in early RA will greatly enhance our ability to minimize the impact of this potentially disabling disease.

    PMID:
    15588978
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk